Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday.

Can-Fite BioPharma Stock Down 3.1 %

Can-Fite BioPharma stock opened at $1.26 on Wednesday. The stock has a market cap of $4.46 million, a P/E ratio of -0.70 and a beta of 1.37. Can-Fite BioPharma has a twelve month low of $1.22 and a twelve month high of $4.69. The company’s 50-day moving average price is $1.56 and its two-hundred day moving average price is $1.78.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers lifted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.